相关实验视频
Updated: May 24, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
在墨西哥管理妊娠期糖尿病的战略框架
Luis Alberto Martinez-Juarez1,2, Héctor Gallardo-Rincón3, Rodrigo Saucedo-Martínez4
1Johns Hopkins Center for Humanitarian Health, 615 N. Wolfe Street, Baltimore, MD, 21205, USA.
Global health research and policy
|February 28, 2025
概括
在墨西哥,妊娠期糖尿病 (GDM) 在10-14%的怀孕中被低诊断,导致严重的健康风险. 迫切需要采取政策行动,改善查,数字健康和患者教育,以获得更好的结果.
科学领域:
- 公共卫生 公共卫生
- 孕产妇健康 孕产妇健康
- 卫生政策 卫生政策
背景情况:
- 孕期糖尿病 (GDM) 影响到墨西哥10-14%的怀孕.
- 目前的检测率非常低,约为5.1%.
- 低诊断导致母亲和婴儿的重大健康风险,并表明系统性医疗保健失败.
研究的目的:
- 突出墨西哥GDM检测和管理的关键差距.
- 确定导致因素,如查不足和数字健康解决方案的碎片化.
- 倡导政策变化,以改善GDM监测和护理.
主要方法:
- 分析墨西哥GDM流行率和检测率.
- 识别医疗保健获取和管理中的系统性问题.
- 关于GDM的现有医疗保健政策的审查.
主要成果:
- 在GDM患病率和确诊病例之间存在显著的差异.
- 获得护理的机会不均,特别是在农村地区,有助于诊断不足.
- 缺乏综合数字健康解决方案阻碍了GDM的一致管理.
结论:
- 需要采取紧急,协调的政策行动,以标准化GDM查.
- 加强数字卫生基础设施对于监督和管理至关重要.
- 针对GDM意识和教育的公共卫生活动对于早期干预和改善母婴健康结果至关重要.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Pathophysiology of Diabetes
842
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
842
Diabetes: Management and Pharmacotherapy
227
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
227
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Oral Hypoglycemic Agents: Biguanides and Glitazones
151
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
151

